Linden Thomas Advisory Services LLC Raises Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Linden Thomas Advisory Services LLC grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 21.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,639 shares of the biopharmaceutical company’s stock after purchasing an additional 5,732 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Catalyst Pharmaceuticals were worth $681,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 681 shares in the last quarter. XTX Topco Ltd raised its stake in Catalyst Pharmaceuticals by 7.5% during the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 773 shares during the period. Sei Investments Co. lifted its holdings in Catalyst Pharmaceuticals by 1.3% in the 2nd quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company’s stock worth $1,308,000 after purchasing an additional 1,098 shares in the last quarter. Assetmark Inc. grew its holdings in Catalyst Pharmaceuticals by 2.4% during the 3rd quarter. Assetmark Inc. now owns 72,245 shares of the biopharmaceutical company’s stock valued at $1,436,000 after buying an additional 1,704 shares in the last quarter. Finally, Summit Global Investments grew its holdings in Catalyst Pharmaceuticals by 2.6% during the 3rd quarter. Summit Global Investments now owns 77,292 shares of the biopharmaceutical company’s stock valued at $1,537,000 after buying an additional 1,923 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CPRX shares. Stephens started coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective for the company. Bank of America reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. HC Wainwright increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. Finally, StockNews.com lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $32.86.

Insider Activity

In related news, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $22.55 on Monday. The company has a market capitalization of $2.69 billion, a P/E ratio of 19.11, a P/E/G ratio of 2.28 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a one year low of $13.12 and a one year high of $24.27. The stock has a 50 day moving average price of $21.79 and a 200-day moving average price of $20.52.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.